Share
Frederic Desdouits
Orano has appointed Frederic Desdouits as Chief Executive Officer of its subsidiary Orano Med, a biotechnology company focused on developing targeted alpha therapies for oncology.
With extensive experience across the pharmaceutical and biotechnology sectors, Frederic Desdouits is expected to lead Orano Med’s development across key strategic and operational areas. His responsibilities will include advancing the company’s diversified pipeline of lead-212-based targeted alpha therapies, spanning early-stage identification through to clinical development, both internally and in collaboration with external partners.
Orano Med’s current pipeline comprises one advanced clinical program and three Phase 1 clinical studies. The company is also strengthening its industrial capabilities to support the future commercial-scale production of lead-212 targeted alpha therapies.
Prior to joining Orano Med, Frederic Desdouits served as Chief Executive Officer of TreeFrog Therapeutics, a French biotechnology company specializing in stem cell-based therapies. He has also held leadership roles at Seqens, where he headed pharmaceutical activities, and at Pierre Fabre, where he oversaw business development and U.S. pharmaceutical operations. Earlier in his career, he co-founded Bionest Partners, a strategy and financial consulting firm dedicated to healthcare, and led the European pharmaceutical and biotechnology equity research team at Exane BNP Paribas. He began his professional journey in pharmaceutical research.
Since 2022, he has been a member of the Orano Med Governing Board and also serves as Vice President of the French industry association France Biotech.
Frederic Desdouits holds a degree from École Polytechnique, a PhD in Neurosciences from the University of Paris VI (Sorbonne), and completed postdoctoral research at The Rockefeller University in New York.
